{"id":4822,"date":"2026-01-05T14:47:00","date_gmt":"2026-01-05T14:47:00","guid":{"rendered":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/"},"modified":"2026-01-05T14:47:00","modified_gmt":"2026-01-05T14:47:00","slug":"first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s","status":"publish","type":"post","link":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/","title":{"rendered":"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div id=\"RegularArticle-ArticleBody-5\" data-module=\"ArticleBody\" data-test=\"articleBody-2\" data-analytics=\"RegularArticle-articleBody-5-2\"><span class=\"HighlightShare-hidden\" style=\"top:0;left:0\"\/><\/p>\n<div class=\"InlineImage-imageEmbed\" id=\"ArticleBody-InlineImage-108231180\" data-test=\"InlineImage\">\n<div class=\"InlineImage-wrapper\">\n<div>\n<p>The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025.<\/p>\n<p>Tom Little | Reuters<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"group\">\n<p><span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-1\"><a href=\"https:\/\/www.cnbc.com\/quotes\/NVO\/\">Novo Nordisk<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span> will start rolling out the <a href=\"https:\/\/www.cnbc.com\/2025\/12\/22\/fda-approves-first-glp-1-pill-for-obesity-from-novo-nordisk.html\">first-ever GLP-1 pill for weight loss<\/a> in the U.S. on Monday, the company announced, marking a <a href=\"https:\/\/www.cnbc.com\/2025\/12\/16\/healthy-returns-obesity-pills-from-novo-nordisk-eli-lilly-are-coming.html\">new chapter of obesity treatment<\/a> in the U.S.\u00a0<\/p>\n<p>The drug&#8217;s cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose. That fuels hopes that pills could help address the <a href=\"https:\/\/www.cnbc.com\/2024\/03\/18\/wegovy-heart-health-insurance-coverage.html\">long-standing affordability hurdles<\/a> tied to the weekly injections dominating the weight loss drug market. <\/p>\n<p>The official launch of the oral drug, called the <a href=\"https:\/\/www.wegovy.com\/about-wegovy\/the-wegovy-pill.html\" target=\"_blank\">Wegovy pill<\/a>, comes just two weeks after U.S. regulators <a href=\"https:\/\/www.prnewswire.com\/news-releases\/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html\" target=\"_blank\">cleared the treatment<\/a>.\u00a0<\/p>\n<p>The starting dose of 1.5 milligrams is available at more than 70,000 U.S. pharmacies such as <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-7\"><a href=\"https:\/\/www.cnbc.com\/quotes\/CVS\/\">CVS<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span> and <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-8\"><a href=\"https:\/\/www.cnbc.com\/quotes\/COST\/\">Costco<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span>, as well as select telehealth providers, including Ro, LifeMD, <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-9\"><a href=\"https:\/\/www.cnbc.com\/quotes\/WW\/\">Weight Watchers<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span>, GoodRx and Novo Nordisk&#8217;s NovoCare Pharmacy. The higher, remaining doses of the pill will be available to patients by the end of the week, Novo Nordisk said.\u00a0<\/p>\n<p>Cash-paying patients can pay $149 per month for the starting dose. The 4-milligram dose of the pill will also be available for $149 per month through April 15, then $199 per month after that.\u00a0<\/p>\n<p>The highest doses of the Wegovy pill \u2013 9 milligrams and 25 milligrams \u2013 will be available for $299 per month. Patients with insurance coverage for the drug can pay as little as $25 per month for the treatment.\u00a0<\/p>\n<p>Cash-paying patients will also be able to access the starting dose of the pill for $149 per month on President <a href=\"https:\/\/www.cnbc.com\/donald-trump\/\">Donald Trump<\/a>&#8216;s direct-to-consumer website, TrumpRx, under <a href=\"https:\/\/www.cnbc.com\/2025\/11\/06\/trump-eli-lilly-novo-nordisk-deal-obesity-drug-prices.html\">a deal Novo Nordisk struck<\/a> with his administration in November. The site also launches in January, though it&#8217;s unclear when.\u00a0<\/p>\n<p>Novo Nordisk on Monday said the pill&#8217;s availability &#8220;opens new possibilities&#8221; for the more than 100 million Americans living with obesity.\u00a0<\/p>\n<p>Injections from Novo Nordisk and its chief rival, <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-12\"><a href=\"https:\/\/www.cnbc.com\/quotes\/LLY\/\">Eli Lilly<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span>, carry a list price of roughly $1,000 per month. But both companies <a href=\"https:\/\/www.cnbc.com\/2025\/12\/01\/eli-lilly-prices-zepbound-weight-loss-drug-vials.html\">offer lower cash-pay prices<\/a> for their shots that range from $299 to $499 monthly, depending on the dose.\u00a0<\/p>\n<p>Pills are the <a href=\"https:\/\/www.cnbc.com\/2025\/11\/02\/whats-next-for-the-weight-loss-drug-market-pills-rivals-insurance.html\">next battleground<\/a> for the two companies, which established the booming GLP-1 space that some analysts say could be worth roughly $100 billion by the 2030s. Goldman Sachs analysts said in August that oral drugs could capture a 24% share \u2014 or around $22 billion \u2014 of the 2030 global weight loss drug market.<\/p>\n<p>The launch of Novo Nordisk&#8217;s daily oral drug on Monday gives the company a clear head start. The Food and Drug Administration approved the treatment on Dec. 22 and will decide whether to clear a rival pill from Eli Lilly later this year.\u00a0<\/p>\n<\/div>\n<div class=\"group\">\n<div class=\"RelatedContent-relatedContent\" id=\"RegularArticle-RelatedContent-1\">\n<div class=\"RelatedContent-container\">\n<div class=\"RelatedContent-nonCollapsibleContent\">\n<h2 class=\"RelatedContent-header\">More CNBC health coverage<\/h2>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"group\">\n<p>The FDA also approved Novo Nordisk&#8217;s pill for use to reduce the risk of major cardiovascular events, such as death, heart attack or stroke, in adults with obesity and established cardiovascular disease.\u00a0<\/p>\n<p>That&#8217;s <a href=\"https:\/\/www.cnbc.com\/2024\/03\/08\/novo-nordisks-wegovy-wins-fda-approval-for-heart-health-benefits-in-move-that-could-expand-insurance-coverage.html\">consistent with the approval label<\/a> of the company&#8217;s blockbuster weight loss drug Wegovy, which shares the same active ingredient, semaglutide. Both work by mimicking the gut hormone GLP-1 to suppress appetite.<\/p>\n<p>&#8220;This moment is about changing what&#8217;s possible in weight management, and to make that possible, we have worked to ensure [the Wegovy pill] is affordable and accessible to those who need it, however they choose to receive their care,&#8221; said Ed Cinca, Novo Nordisk&#8217;s senior vice president of marketing and patient solutions, in a release.\u00a0<\/p>\n<p>People who take Novo Nordisk&#8217;s pill have to wait 30 minutes before eating or drinking each day.<\/p>\n<p>In a phase three trial that followed more than 300 adults with obesity and not diabetes, the highest dose of Novo Nordisk&#8217;s oral semaglutide helped patients lose up to 16.6% of their weight on average after 64 weeks. That weight loss was 13.6% when the company analyzed all patients regardless of whether they stopped the drug.<\/p>\n<p>The pill appears to be slightly more effective than Eli Lilly&#8217;s experimental oral drug, which does not have dietary restrictions.\u00a0<\/p>\n<\/div>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.cnbc.com\/2026\/01\/05\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-us.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity&#8230;<\/p>\n<p class=\"more-link-wrap\"><a href=\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/\" class=\"more-link\">Read More<span class=\"screen-reader-text\"> &ldquo;First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0&rdquo;<\/span> &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":4823,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108231180-17640121262025-11-24t185244z_352081195_rc263iank3kr_rtrmadp_0_novo-nordisk.jpeg?v=1765918401&w=1920&h=1080","fifu_image_alt":"","footnotes":""},"categories":[4],"tags":[73,74,75,69,77,930,858,2615,1110,488,70,259,156,426,558],"class_list":["post-4822","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-biotech-and-pharmaceuticals","tag-biotechnology","tag-breaking-news-business","tag-business","tag-business-news","tag-costco-wholesale-corp","tag-cvs-health-corp","tag-donald-j-trump","tag-donald-trump","tag-eli-lilly-and-co","tag-health-care-industry","tag-novo-nordisk-a-s","tag-pharmaceuticals","tag-united-states","tag-ww-international-inc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.8 (Yoast SEO v22.1) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0 - Breaking News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0\" \/>\n<meta property=\"og:description\" content=\"The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity...Read More &ldquo;First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0&rdquo; &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/\" \/>\n<meta property=\"og:site_name\" content=\"Breaking News\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T14:47:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108231180-17640121262025-11-24t185244z_352081195_rc263iank3kr_rtrmadp_0_novo-nordisk.jpeg?v=1765918401&w=1920&h=1080\" \/>\n<meta name=\"author\" content=\"Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108231180-17640121262025-11-24t185244z_352081195_rc263iank3kr_rtrmadp_0_novo-nordisk.jpeg?v=1765918401&w=1920&h=1080\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/\"},\"author\":{\"name\":\"Admin\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a\"},\"headline\":\"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0\",\"datePublished\":\"2026-01-05T14:47:00+00:00\",\"dateModified\":\"2026-01-05T14:47:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/\"},\"wordCount\":664,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"},\"keywords\":[\"Biotech and Pharmaceuticals\",\"Biotechnology\",\"Breaking News: Business\",\"Business\",\"business news\",\"Costco Wholesale Corp\",\"CVS Health Corp\",\"Donald J. Trump\",\"Donald Trump\",\"Eli Lilly and Co\",\"Health care industry\",\"Novo Nordisk A\/S\",\"Pharmaceuticals\",\"United States\",\"WW International Inc\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/\",\"url\":\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/\",\"name\":\"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0 - Breaking News\",\"isPartOf\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#website\"},\"datePublished\":\"2026-01-05T14:47:00+00:00\",\"dateModified\":\"2026-01-05T14:47:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ventil.rs\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ventil.rs\/blog\/#website\",\"url\":\"https:\/\/ventil.rs\/blog\/\",\"name\":\"Breaking News\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ventil.rs\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\",\"name\":\"Breaking News\",\"url\":\"https:\/\/ventil.rs\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png\",\"contentUrl\":\"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png\",\"width\":1445,\"height\":591,\"caption\":\"Breaking News\"},\"image\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a\",\"name\":\"Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g\",\"caption\":\"Admin\"},\"sameAs\":[\"https:\/\/ventil.rs\/blog\"],\"url\":\"https:\/\/ventil.rs\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0 - Breaking News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/","og_locale":"en_US","og_type":"article","og_title":"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0","og_description":"The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity...Read More &ldquo;First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0&rdquo; &raquo;","og_url":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/","og_site_name":"Breaking News","article_published_time":"2026-01-05T14:47:00+00:00","og_image":[{"url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108231180-17640121262025-11-24t185244z_352081195_rc263iank3kr_rtrmadp_0_novo-nordisk.jpeg?v=1765918401&w=1920&h=1080"}],"author":"Admin","twitter_card":"summary_large_image","twitter_image":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108231180-17640121262025-11-24t185244z_352081195_rc263iank3kr_rtrmadp_0_novo-nordisk.jpeg?v=1765918401&w=1920&h=1080","twitter_misc":{"Written by":"Admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/#article","isPartOf":{"@id":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/"},"author":{"name":"Admin","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a"},"headline":"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0","datePublished":"2026-01-05T14:47:00+00:00","dateModified":"2026-01-05T14:47:00+00:00","mainEntityOfPage":{"@id":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/"},"wordCount":664,"commentCount":0,"publisher":{"@id":"https:\/\/ventil.rs\/blog\/#organization"},"keywords":["Biotech and Pharmaceuticals","Biotechnology","Breaking News: Business","Business","business news","Costco Wholesale Corp","CVS Health Corp","Donald J. Trump","Donald Trump","Eli Lilly and Co","Health care industry","Novo Nordisk A\/S","Pharmaceuticals","United States","WW International Inc"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/ventil.rs\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/","url":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/","name":"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0 - Breaking News","isPartOf":{"@id":"https:\/\/ventil.rs\/blog\/#website"},"datePublished":"2026-01-05T14:47:00+00:00","dateModified":"2026-01-05T14:47:00+00:00","breadcrumb":{"@id":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ventil.rs\/blog\/health\/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-u-s\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ventil.rs\/blog\/"},{"@type":"ListItem","position":2,"name":"First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/ventil.rs\/blog\/#website","url":"https:\/\/ventil.rs\/blog\/","name":"Breaking News","description":"","publisher":{"@id":"https:\/\/ventil.rs\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ventil.rs\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ventil.rs\/blog\/#organization","name":"Breaking News","url":"https:\/\/ventil.rs\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png","contentUrl":"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png","width":1445,"height":591,"caption":"Breaking News"},"image":{"@id":"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a","name":"Admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g","caption":"Admin"},"sameAs":["https:\/\/ventil.rs\/blog"],"url":"https:\/\/ventil.rs\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts\/4822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/comments?post=4822"}],"version-history":[{"count":0,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts\/4822\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/media\/4823"}],"wp:attachment":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/media?parent=4822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/categories?post=4822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/tags?post=4822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}